These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 19430786)

  • 1. The influence of Bz-DOTA and CHX-A''-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for (114m)In-mediated targeting therapy.
    Tolmachev V; Wållberg H; Andersson K; Wennborg A; Lundqvist H; Orlova A
    Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1460-8. PubMed ID: 19430786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of [(111/114m)In]CHX-A''-DTPA-ZHER2:342, an affibody ligand coniugate for targeting of HER2-expressing malignant tumors.
    Orlova A; Rosik D; Sandström M; Lundqvist H; Einarsson L; Tolmachev V
    Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):314-23. PubMed ID: 17464277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
    Tolmachev V; Orlova A; Pehrson R; Galli J; Baastrup B; Andersson K; Sandström M; Rosik D; Carlsson J; Lundqvist H; Wennborg A; Nilsson FY
    Cancer Res; 2007 Mar; 67(6):2773-82. PubMed ID: 17363599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
    Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
    J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a maleimido derivative of CHX-A'' DTPA for site-specific labeling of affibody molecules.
    Tolmachev V; Xu H; Wållberg H; Ahlgren S; Hjertman M; Sjöberg A; Sandström M; Abrahmsén L; Brechbiel MW; Orlova A
    Bioconjug Chem; 2008 Aug; 19(8):1579-87. PubMed ID: 18620447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.
    Perols A; Honarvar H; Strand J; Selvaraju R; Orlova A; Karlström AE; Tolmachev V
    Bioconjug Chem; 2012 Aug; 23(8):1661-70. PubMed ID: 22768790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
    Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V
    J Nucl Med; 2009 May; 50(5):781-9. PubMed ID: 19372467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (186)Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours.
    Orlova A; Tran TA; Ekblad T; Karlström AE; Tolmachev V
    Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):260-9. PubMed ID: 19771426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody.
    Malmberg J; Sandström M; Wester K; Tolmachev V; Orlova A
    Nucl Med Biol; 2011 Nov; 38(8):1093-102. PubMed ID: 22137850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors.
    Orlova A; Tran T; Widström C; Engfeldt T; Eriksson Karlström A; Tolmachev V
    Int J Mol Med; 2007 Sep; 20(3):397-404. PubMed ID: 17671747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus.
    Lindberg H; Hofström C; Altai M; Honorvar H; Wållberg H; Orlova A; Ståhl S; Gräslund T; Tolmachev V
    Tumour Biol; 2012 Jun; 33(3):641-51. PubMed ID: 22249974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts.
    Malmberg J; Perols A; Varasteh Z; Altai M; Braun A; Sandström M; Garske U; Tolmachev V; Orlova A; Karlström AE
    Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):481-92. PubMed ID: 22322933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation of
    Pandey U; Kameswaran M; Gamre N; Dash A
    J Labelled Comp Radiopharm; 2019 Apr; 62(4):158-165. PubMed ID: 30663095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules.
    Westerlund K; Honarvar H; Norrström E; Strand J; Mitran B; Orlova A; Eriksson Karlström A; Tolmachev V
    Mol Pharm; 2016 May; 13(5):1668-78. PubMed ID: 27010700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody
    Liu Y; Vorobyeva A; Xu T; Orlova A; Loftenius A; Bengtsson T; Jonasson P; Tolmachev V; Frejd FY
    Pharmaceutics; 2021 Jun; 13(6):. PubMed ID: 34200197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules.
    Ahlgren S; Orlova A; Rosik D; Sandström M; Sjöberg A; Baastrup B; Widmark O; Fant G; Feldwisch J; Tolmachev V
    Bioconjug Chem; 2008 Jan; 19(1):235-43. PubMed ID: 18163536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
    Orlova A; Wållberg H; Stone-Elander S; Tolmachev V
    J Nucl Med; 2009 Mar; 50(3):417-25. PubMed ID: 19223403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules.
    Tolmachev V; Mume E; Sjöberg S; Frejd FY; Orlova A
    Eur J Nucl Med Mol Imaging; 2009 Apr; 36(4):692-701. PubMed ID: 19066886
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.